Adagio Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

Provided By Globe Newswire

Last update: Aug 15, 2022

$475 Million in Cash and Cash Equivalents to Support Operating Runway into Second Quarter of 2024

Integrated Discovery Platform Identifies Multiple New Candidates for COVID-19 Prevention and Treatment with Plans to Enter Clinical Trials in the First Quarter of 2023